


## Roche's Devmanyu Singh Explores Molecular Tumor Board Trends and Challenges in APAC Region at Precision Cancer Treatment Forum

01 December 2023 | News

**"In a pivotal presentation at the Asia Pacific Forum on Precision Cancer Treatment at Taiwan Healthcare+ Expo 2023, Roche's Integrated Health Solution Lead sheds light on the evolving landscape of Molecular Tumor Boards, addressing key trends and challenges in precision cancer treatment."**



Devmanyu Singh, Integrated Health Solution Lead at Roche, takes center stage at the Asia Pacific Forum on Precision Cancer Treatment to delve into the latest advancements and challenges surrounding Molecular Tumor Boards in the APAC region. In an era where personalized medicine transforms cancer care, Singh's expertise promises valuable insights for shaping future treatment strategies.

As precision medicine revolutionizes cancer care, Molecular Tumor Boards play a crucial role in navigating the complex genomic landscape of tumors. Singh, an esteemed expert, will specifically address current trends and challenges in the APAC region, ensuring that diverse populations benefit from advancements in precision cancer treatment.

"Precision medicine has transformed cancer care, and Molecular Tumor Boards harness genomics to tailor treatment plans for individual patients," said Devmanyu Singh. "Understanding unique APAC trends is essential for optimizing boards and ensuring patients benefit from the latest advancements."

The Asia Pacific Forum on Precision Cancer Treatment serves as a platform for collaboration among experts, researchers, and healthcare professionals. Singh's presentation promises to be a highlight, offering perspectives on adapting Molecular Tumor Boards to the specific needs of the APAC population.

Precision oncology demands a nuanced understanding of the sensitivity, specificity, and limitations of oncology tests used to profile a patient's tumor. Beyond test proficiency, it requires specialized knowledge to interpret the detected alterations in a tumor as clinically relevant or 'actionable.' An alteration is deemed actionable if it aids in diagnosis, provides

prognostic or risk information, reveals inherited susceptibilities to cancer, and/or holds therapeutic value.

The landscape of actionability is in constant flux, influenced by factors such as approved targeted therapies, updates to clinical guidelines, new clinical trials, evolving data on individual alterations' contributions to cancer development, and associations between genes and specific alterations with responses to particular drugs. Navigating this intricate landscape poses a challenge for many clinicians.

The Molecular Tumor Board functions as a solution to this complexity. It serves as a mechanism where clinical experts offer state-of-the-art and evidence-based assessments of molecular test results. The goal is to guide the interpretation and integration of these results into clinical practice for cancer patients treated at UCSF or its affiliated hospitals.

Roche, a global healthcare leader, continues to drive innovations in precision medicine. Singh's role as Integrated Health Solution Lead underscores Roche's commitment to improving patient outcomes through groundbreaking advancements in cancer treatment.